Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John H Lawrence

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Communicative & Integrative Biology|July 13, 2013
Canopy and knowledge gaps when invasive alien insects remove foundation speciesThomas E Marler, John H Lawrence
Journal of Medical Economics|August 19, 2014
Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient populationAlpesh Amin, Michael Stokes, Dinara Makenbaeva, et al.
Annals of the New York Academy of Sciences|November 8, 2014
Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillationMichael S Hanna, Puneet Mohan, Robert Knabb, et al.
The American Journal of Cardiology|May 21, 2005
Antianginal efficacy of omapatrilat in patients with chronic angina pectorisBernard R Chaitman, Alla Y Ivleva, Marek Ujda, et al.
Journal of the American College of Cardiology|March 10, 2018
Digoxin and Mortality in Patients With Atrial FibrillationRenato D Lopes, Roberto Rordorf, Gaetano M De Ferrari, et al.
The New England Journal of Medicine|February 8, 2019
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa InhibitorsStuart J Connolly, Mark Crowther, John W Eikelboom, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Communicative & Integrative Biology|July 13, 2013
Canopy and knowledge gaps when invasive alien insects remove foundation speciesThomas E Marler, John H Lawrence
Journal of Medical Economics|August 19, 2014
Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient populationAlpesh Amin, Michael Stokes, Dinara Makenbaeva, et al.
Annals of the New York Academy of Sciences|November 8, 2014
Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillationMichael S Hanna, Puneet Mohan, Robert Knabb, et al.
The American Journal of Cardiology|May 21, 2005
Antianginal efficacy of omapatrilat in patients with chronic angina pectorisBernard R Chaitman, Alla Y Ivleva, Marek Ujda, et al.
Journal of the American College of Cardiology|March 10, 2018
Digoxin and Mortality in Patients With Atrial FibrillationRenato D Lopes, Roberto Rordorf, Gaetano M De Ferrari, et al.
The New England Journal of Medicine|February 8, 2019
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa InhibitorsStuart J Connolly, Mark Crowther, John W Eikelboom, et al.
Pageof 1